{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:02:36Z","timestamp":1789549356242,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10067-026-08367-6","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:07:30Z","timestamp":1787670450000},"page":"5957-5961","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health equity in rheumatology\u2014the uneven landscape of cellular therapy"],"prefix":"10.1007","volume":"45","author":[{"given":"Sharon","family":"Dowell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6043-7277","authenticated-orcid":false,"given":"Grace C","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"1","key":"8367_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","volume":"60","author":"A Rampotas","year":"2025","unstructured":"Rampotas A, Richter J, Isenberg D, Roddie C (2025) CAR-T cell therapy embarks on autoimmune disease. Bone Marrow Transplant 60(1):6\u20139","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"8367_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/237946151800400102","volume":"4","author":"P Braveman","year":"2018","unstructured":"Braveman P, Arkin E, Orleans T, Proctor D, Acker J, Plough A (2018) What is health equity? Behavioral Science & Policy 4(1):1\u201314","journal-title":"Behavioral Science & Policy"},{"key":"8367_CR3","first-page":"1","volume":"17","author":"G Wright","year":"2025","unstructured":"Wright G, Zueger P, Copley-Merriman C, Khan S, Costello J, Krumbach A et al (2025) Health disparities in rheumatology in the United States. Open Access Rheumatol Res Rev 17:1\u201312","journal-title":"Open Access Rheumatol Res Rev"},{"issue":"3","key":"8367_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/art.43397","volume":"78","author":"S Dowell","year":"2026","unstructured":"Dowell S, Banbury B, Jenkins C, Holladay EE, Xie F, Zhang J et al (2026) The influence of race, ethnicity and historical redlining on psoriatic disease burden and clinical outcomes. Arthritis Rheumatol 78(3):644\u2013653","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"8367_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/acr2.11532","volume":"5","author":"S Dowell","year":"2023","unstructured":"Dowell S, Yun H, Curtis JR, Chen L, Xie F, Pedra-Nobre M et al (2023) Geographic variation in disease burden and mismatch in care of patients with rheumatoid arthritis in the United States. ACR Open Rheumatology 5(4):181\u2013189","journal-title":"ACR Open Rheumatology"},{"issue":"1","key":"8367_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.17925\/RMD.2023.2.1.42","volume":"2","author":"NK Sandhu","year":"2023","unstructured":"Sandhu NK, Wright G, Fajardo K, Gupta L (2023) Health equity in rheumatology: a global health perspective. Rheumatology (Oxford) 2(1):42\u201345","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"8367_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph22030325","volume":"22","author":"M Sharma","year":"2025","unstructured":"Sharma M, Akhter MS, Roy S, Srejon R (2025) Future issues in global health: challenges and conundrums. Int J Environ Res Public Health 22(3):325","journal-title":"Int J Environ Res Public Health"},{"key":"8367_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1519671","volume":"15","author":"Y Kong","year":"2025","unstructured":"Kong Y, Li J, Zhao X, Wu Y, Chen L (2025) CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity. Front Immunol 15:1519671","journal-title":"Front Immunol"},{"issue":"6","key":"8367_CR9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S et al (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385(6):567\u2013569","journal-title":"N Engl J Med"},{"issue":"8","key":"8367_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S et al (2024) CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N Engl J Med 390(8):687\u2013700","journal-title":"N Engl J Med"},{"key":"8367_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1630569","volume":"16","author":"X Xu","year":"2025","unstructured":"Xu X, Su S-H (2025) CAR-T cell therapies in autoimmune rheumatic diseases: a brief report on the clinical trial landscape, current status, and future perspectives. Front Immunol 16:1630569","journal-title":"Front Immunol"},{"key":"8367_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1583116","volume":"16","author":"L-Y Cao","year":"2025","unstructured":"Cao L-Y, Zhao Y, Chen Y, Ma P, Xie J-C, Pan X-M et al (2025) CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials.gov insights. Front Immunol 16:1583116","journal-title":"Front Immunol"},{"issue":"4","key":"8367_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkae059","volume":"8","author":"M Di","year":"2024","unstructured":"Di M, Potnis KC, Long JB, Isufi I, Foss F, Seropian S et al (2024) Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectr 8(4):pkae059","journal-title":"JNCI Cancer Spectr"},{"issue":"19","key":"8367_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph191912366","volume":"19","author":"G Choi","year":"2022","unstructured":"Choi G, Shin G, Bae S (2022) Price and prejudice? The value of chimeric antigen receptor (CAR) T-cell therapy. Int J Environ Res Public Health 19(19):12366","journal-title":"Int J Environ Res Public Health"},{"key":"8367_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bglo.2025.100051","author":"DV Cl\u00e9","year":"2025","unstructured":"Cl\u00e9 DV, Donadel CD, Calado RT (2025) CAR-T in resource-limited regions. Blood Glob Hematol. https:\/\/doi.org\/10.1016\/j.bglo.2025.100051","journal-title":"Blood Glob Hematol"},{"issue":"14","key":"8367_CR16","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1182\/blood.2025030872","volume":"147","author":"AY Ge","year":"2026","unstructured":"Ge AY, Feldman WB, Kaiser MF, Rejeski K, Iacoboni G, Narula G et al (2026) Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries. Blood 147(14):1521\u20131531","journal-title":"Blood"},{"issue":"4","key":"8367_CR17","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/bjh.19997","volume":"206","author":"D Dragoi","year":"2025","unstructured":"Dragoi D, Cusworth S, Oldham L, Sanderson R, Norman J, Chandan JS et al (2025) CAR T access and outcomes in large B-cell lymphoma according to ethnicity and socioeconomic deprivation in the UK. Br J Haematol 206(4):1178\u20131185","journal-title":"Br J Haematol"},{"issue":"5","key":"8367_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10067-014-2841-6","volume":"34","author":"M Al Maini","year":"2015","unstructured":"Al Maini M, Adelowo F, Al Saleh J, Al Weshahi Y, Burmester G-R, Cutolo M et al (2015) The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases. Clin Rheumatol 34(5):819\u201329","journal-title":"Clin Rheumatol"},{"issue":"4","key":"8367_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/acr.23518","volume":"70","author":"DF Battafarano","year":"2018","unstructured":"Battafarano DF, Ditmyer M, Bolster MB, Fitzgerald JD, Deal C, Bass AR et al (2018) 2015 American College of Rheumatology Workforce Study: Supply and Demand Projections of Adult Rheumatology Workforce, 2015\u20132030. Arthritis Care Res 70(4):617\u2013626","journal-title":"Arthritis Care Res"},{"issue":"7","key":"8367_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","volume":"28","author":"N Ahmed","year":"2022","unstructured":"Ahmed N, Shahzad M, Shippey E, Bansal R, Mushtaq MU, Mahmoudjafari Z et al (2022) Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access. Transplant Cell Ther 28(7):358\u2013364","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"8367_CR21","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/j.ccell.2023.10.002","volume":"41","author":"H Badr","year":"2023","unstructured":"Badr H, Rouce R, Scheurer ME, Lulla P, Mims M, Reddy P (2023) Bringing CAR T cell therapy trials to underserved populations. Cancer Cell 41(12):2007\u201310","journal-title":"Cancer Cell"},{"issue":"1","key":"8367_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11899-024-00747-6","volume":"20","author":"N Islam","year":"2024","unstructured":"Islam N, Budvytyte L, Khera N, Hilal T (2024) Disparities in clinical trial enrollment\u2013 focus on CAR-T and bispecific antibody therapies. Curr Hematol Malig Rep 20(1):1","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"8367_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71457","volume":"15","author":"H Warnakulasuriya","year":"2026","unstructured":"Warnakulasuriya H, Tiwari R (2026) Racial and socioeconomic healthcare disparities in access to chimeric antigen receptor T (CAR-T) cell therapy for blood cancers. Cancer Med 15(2):e71457","journal-title":"Cancer Med"},{"issue":"3","key":"8367_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L (2020) \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 19(3):185\u2013199","journal-title":"Nat Rev Drug Discov"},{"key":"8367_CR25","unstructured":"CMS. Cell and gene therapy (CGT) access model: overview factsheet. Baltimore, MD: U.S. Centers for Medicare & Medicaid Services; 2024. Accessed July 18 2026."},{"key":"8367_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41434-023-00425-x","volume":"31","author":"S Saleh","year":"2024","unstructured":"Saleh S, Dabbous O, Sullivan SD, Ankleshwaria D, Trombini D, Toumi M et al (2024) A practical approach for adoption of a hub and spoke model for cell and gene therapies in low- and middle-income countries: framework and case studies. Gene Ther 31:1\u201311","journal-title":"Gene Ther"},{"key":"8367_CR27","volume-title":"WHO approach towards the development of a global regulatory framework for cell and gene therapy products","author":"World Health O.","year":"2022","unstructured":"World Health O. (2022) WHO approach towards the development of a global regulatory framework for cell and gene therapy products. World Health Organization, Geneva"},{"key":"8367_CR28","unstructured":"Gandu A, Prathyusha K. CAR-T therapy in rheumatoid arthritis: a health systems analysis of cost and global equity. Arthritis & Rheumatology. 2025;77(suppl 9)."}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08367-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08367-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08367-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:04:44Z","timestamp":1789545884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08367-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8367"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08367-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sharon Dowell MBBS serves as principal investigator on an industry-sponsored CAR-T cell therapy clinical trial. Grace Wright MD PhD serves as consultant\/speaker for Abbvie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, FATE Therapeutics, Johnson & Johnson, Novartis, Pfizer, SOBI, and UCB.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}